Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has 4 years of FCF Margin data on record, last reported at 344243100.0% in Q4 2023.

  • On a quarterly basis, FCF Margin fell 34423750523.0% to 344243100.0% in Q4 2023 year-over-year; TTM through Sep 2024 was 1724492300.0%, a 172448668417.0% decrease, with the full-year FY2023 number at 6947.87%, up 730549.0% from a year prior.
  • FCF Margin reached 344243100.0% in Q4 2023 per IKT's latest filing, down from 5159.16% in the prior quarter.
  • Over the last five years, FCF Margin for IKT hit a ceiling of 200.41% in Q3 2020 and a floor of 344243100.0% in Q4 2023.
  • A 4-year average of 21539540.75% and a median of 4540.49% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: soared 20509540bps in 2022, then crashed 2000000000bps in 2023.
  • Tracing IKT's FCF Margin over 4 years: stood at 555.42% in 2020, then plummeted by -37833bps to 210690.17% in 2021, then soared by 97bps to 5594.77% in 2022, then plummeted by -6152840bps to 344243100.0% in 2023.
  • Business Quant data shows FCF Margin for IKT at 344243100.0% in Q4 2023, 5159.16% in Q3 2023, and 3921.82% in Q2 2023.